vs
Side-by-side financial comparison of Hologic (HOLX) and Ralliant Corp (RAL). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $529.1M, roughly 2.0× Ralliant Corp). Hologic runs the higher net margin — 17.1% vs 7.5%, a 9.6% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -0.5%). Hologic produced more free cash flow last quarter ($215.2M vs $126.6M).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
HOLX vs RAL — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $529.1M |
| Net Profit | $179.1M | $39.9M |
| Gross Margin | 56.0% | 50.8% |
| Operating Margin | 22.6% | 9.8% |
| Net Margin | 17.1% | 7.5% |
| Revenue YoY | 2.5% | -0.5% |
| Net Profit YoY | -10.9% | -56.1% |
| EPS (diluted) | $0.79 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | $529.1M | ||
| Q2 25 | $1.0B | $503.3M | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $988.0M | $531.7M | ||
| Q2 24 | $1.0B | $533.7M | ||
| Q1 24 | $1.0B | — |
| Q4 25 | $179.1M | — | ||
| Q3 25 | $187.2M | $39.9M | ||
| Q2 25 | $194.9M | $47.6M | ||
| Q1 25 | $-17.4M | — | ||
| Q4 24 | $201.0M | — | ||
| Q3 24 | $178.6M | $90.9M | ||
| Q2 24 | $194.5M | $64.8M | ||
| Q1 24 | $169.9M | — |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | 50.8% | ||
| Q2 25 | 56.3% | 49.3% | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | 52.6% | ||
| Q2 24 | 55.4% | 51.5% | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | — | ||
| Q3 25 | 22.6% | 9.8% | ||
| Q2 25 | 24.9% | 11.7% | ||
| Q1 25 | -0.7% | — | ||
| Q4 24 | 22.5% | — | ||
| Q3 24 | 23.3% | 20.9% | ||
| Q2 24 | 24.1% | 19.7% | ||
| Q1 24 | 20.7% | — |
| Q4 25 | 17.1% | — | ||
| Q3 25 | 17.8% | 7.5% | ||
| Q2 25 | 19.0% | 9.5% | ||
| Q1 25 | -1.7% | — | ||
| Q4 24 | 19.7% | — | ||
| Q3 24 | 18.1% | 17.1% | ||
| Q2 24 | 19.2% | 12.1% | ||
| Q1 24 | 16.7% | — |
| Q4 25 | $0.79 | — | ||
| Q3 25 | $0.84 | $0.35 | ||
| Q2 25 | $0.86 | $0.42 | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $0.87 | — | ||
| Q3 24 | $0.75 | $0.81 | ||
| Q2 24 | $0.82 | $0.57 | ||
| Q1 24 | $0.72 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $264.2M |
| Total DebtLower is stronger | $2.5B | $1.1B |
| Stockholders' EquityBook value | $5.2B | $3.0B |
| Total Assets | $9.2B | $5.3B |
| Debt / EquityLower = less leverage | 0.48× | 0.39× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.2B | $264.2M | ||
| Q2 25 | $1.9B | $198.6M | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.2B | — |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | $1.1B | ||
| Q2 25 | $2.5B | $1.1B | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.0B | $3.0B | ||
| Q2 25 | $4.8B | $3.0B | ||
| Q1 25 | $4.6B | — | ||
| Q4 24 | $4.8B | — | ||
| Q3 24 | $5.1B | $4.0B | ||
| Q2 24 | $5.0B | $4.0B | ||
| Q1 24 | $4.8B | — |
| Q4 25 | $9.2B | — | ||
| Q3 25 | $9.0B | $5.3B | ||
| Q2 25 | $8.8B | $5.2B | ||
| Q1 25 | $8.5B | — | ||
| Q4 24 | $8.7B | — | ||
| Q3 24 | $9.2B | — | ||
| Q2 24 | $8.9B | — | ||
| Q1 24 | $8.7B | — |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | 0.39× | ||
| Q2 25 | 0.52× | 0.38× | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $138.6M |
| Free Cash FlowOCF − Capex | $215.2M | $126.6M |
| FCF MarginFCF / Revenue | 20.5% | 23.9% |
| Capex IntensityCapex / Revenue | 1.4% | 2.3% |
| Cash ConversionOCF / Net Profit | 1.28× | 3.47× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | — | ||
| Q3 25 | $355.1M | $138.6M | ||
| Q2 25 | $343.3M | — | ||
| Q1 25 | $169.4M | — | ||
| Q4 24 | $189.3M | — | ||
| Q3 24 | $367.0M | — | ||
| Q2 24 | $405.8M | — | ||
| Q1 24 | $292.4M | — |
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | $126.6M | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — | ||
| Q1 24 | $279.6M | — |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | 23.9% | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — | ||
| Q1 24 | 27.5% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | 2.3% | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | 3.47× | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | — | ||
| Q1 24 | 1.72× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RAL
| Industrial Manufacturing | $111.1M | 21% |
| Defense And Space | $93.6M | 18% |
| Diversified Electronics | $91.0M | 17% |
| Test And Measurement | $76.8M | 15% |
| Communications | $60.7M | 11% |
| Semiconductors | $51.4M | 10% |
| Other Direct End Markets | $44.4M | 8% |
